Therapy of chronic hepatitis b with recombinant human alpha and gamma interferon

Adrian M. Di Bisceglie, Vinod K. Rustgi, Chris Kassianides, Mauricio Lisker‐Melman, Yoon Park, Jeanne G. Waggoner, Jay H. Hoofnagle – 1 February 1990 – Eight patients with chronic hepatitis B entered a pilot study of gamma interferon and alpha interferon in combination. Gamma interferon alone had minimal inhibitory effects on serum levels of hepatitis B virus as monitored by serum HBV DNA and DNA‐polymerase activity. The drug also gave troublesome side effects. In contrast, alpha interferon had more potent inhibitory effects on serum HBV levels and fewer side effects.

Sclerotherapy with alcohol–a two‐edged sword!

S. K. Sarin – 1 February 1990 – Absolute alcohol is a potentially optimal agent for sclerotherapy of esophageal varices. It is cheap and readily available. We compared the efficacy and safety of alcohol with those of a commonly used sclerosing agent, polidocanol. The study was planned to include patients with previous bleeding from esophageal varices randomly assigned to one of the two treatments.

Hemodynamic evaluation of molsidomine: A vasodilator with antianginal properties in patients with alcoholic cirrhosis

Jean Pierre Vinel, Jean‐Luc Monnin, Jean‐Marc Combis, Paul Cales, Herve Desmorat, Jean‐Pierre Pascal – 1 February 1990 – Organic nitrates were reported to reduce portohepatic venous pressure gradient in patients with cirrhosis. However, these drugs lower arterial pressure and are well known to induce tolerace. The aim of the present study was to assess the hemodynamic effects of molsidomine, an antianginal agent, which does not induce tolerance and has little effect on arterial pressure in patients with normal liver, in 13 patients with alcoholic cirrhosis.

Absence of growth‐hormone receptor in hepatocellular carcinoma and cirrhotic liver

Tien‐Chun Chang, Jyh‐Jian Lin, Shan‐Chang Yu, Tien‐Jye Chang – 1 January 1990 – Hepatocellular carcinoma is a hormone‐sensitive tumor. It has been reported that thyroxine and prolactin significantly stimulated hepatoma growth, whereas growth hormone failed to do so. To learn whether the growth hormone receptor is present in human hepatocellular carcinoma, we used radioreceptor assays in samples of human hepatocellular carcinoma. The liver tissues adjacent to hepatocellular carcinoma (mostly cirrhotic) and control liver tissues (taken during various surgical procedures) were also studied.

Subscribe to